	Application No.	Applicant(s)
•	дрисацоп но.	Applicant(s)
Notice of Allemahility	10/685,323	BARRAT ET AL.
Notice of Allowability	Examiner	Art Unit
	Michail A. Belyavskyi	1644
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>05/09/06</u> .		
2. The allowed claim(s) is/are 20,23-27,37, 38 and 41.		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 🗆 11 11 11 11 11 11 11 11 11 11 11 11 11	
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary (Paper No./Mail Date	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	8), 7. 🛛 Examiner's Amendm	nent/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Statemen	nt of Reasons for Allowance
of Biological Material	9.	

Application/Control Number: 10/685,323 Page 2

Art Unit: 1644

ŧ

DETAILED ACTION

1. Applicant's amendment, filed 05/09/06 is acknowledged.

Claims 20, 23 -27, 37, 38 and 41 are pending and allowed.

EXAMINER'S AMENDMENT

- 2. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.
- 3. Authorization for this Examiner's Amendment was given in a telephone interview with Sheela Mohan-Peterson on 06/07/06 and 06/08/06.

In the Claims:

- 4. Claims 22, 39 and 40 have been canceled.
- 5. In claim 20:
 - the phrase -- a combination of -- has been added following the phrase "the stimulatory signal is"
 - the phrase "essentially only IL-10" has been replaced with --
 - a) at least 100 ng of IL-10 per 10⁶ cells and
 - b) less than 1 ng of IL-4 per 10⁶ cells and
 - c) less than 30 pg of IL-5 per 10⁶ cells and/or
 - d) less than 30 pg of IFN-γ per 10⁶ cells --
- 6. In Claim 23:
- in line 2, the phrase -- a -- has been inserted after "suppresses"
- in line 3, the phrase "an antagonist" has been replaced with -- a neutralizing antibody --.

Application/Control Number: 10/685,323 Page 3

Art Unit: 1644

7. In claim 38, line 3 the phrase "antagonists" has been replaced with -- neutralizing antibodies --.

REASONS FOR ALLOWANCE

8. The following is an Examiner's Statement of Reasons for Allowance:

The previous rejection of record, mailed on 03/10/06 is herby withdrawn in view of:

- (i) A Terminal Disclaimer filed on 05/09/06.
- (ii) The Examiner's Amendment set forth supra;

The prior art does not teach or suggest a method of obtaining a regulatory T cells and a population of said cells as recited in claims 20, 23 –27 and 37, 38 and 41.

9. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1644

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskyi, Ph.D. Patent Examiner Technology Center 1600 June 8, 2006

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600